Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts
Our findings support the early use of emicizumab as a safe and effective prophylactic strategy in infants with severe HA. However, the observed inhibitor rate underscores the need for ongoing monitoring and research to optimize care, particularly in vulnerable populations.
Authors
- Ivan Budnik (ORCID: https://orcid.org/0000-0002-6652-2667)
- Tami Brutman‐Barazani (ORCID: https://orcid.org/0009-0009-8651-2501)
- Jesal Patel
- Gili Kenet (ORCID: https://orcid.org/0000-0003-3494-9823)
- Tami Livnat (ORCID: https://orcid.org/0000-0002-1279-2557)
- Sarina Levy‐Mendelovich (ORCID: https://orcid.org/0000-0003-3971-0336)
- Assaf Arie Barg (ORCID: https://orcid.org/0000-0002-8329-8409)
- Einat Avishai
- Rima Dardik
- Jayashree Motwani (ORCID: https://orcid.org/0000-0001-8770-2686)
- Jonathan Lancashire
- Tlalit Barhod
Institutions
- University of Iowa (US)
- Tel Aviv University (IL)
- Sheba Medical Center (IL)
- Birmingham Children's Hospital (GB)
- Edmond and Lily Safra Children's Hospital (IL)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1002/pbc.32118
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00